eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2021-12-30 18 4 795 799 10.13005/bbra/2961 40138 article Paroma Arefin 1 Md Shehan Habib 1 Mohammad Mostafa 1 Dipankar Chakraborty 1 Sreebash Chandra Bhattacharjee 1 Md Saidul Arefin 3 BCSIR Chattogram Laboratories, Bangladesh Council of Scientific and Industrial Research, Bangladesh Institute of Food Science and Technology, Bangladesh Council of Scientific and Industrial Research, Bangladesh Institute of Nutrition and Food Science, University of Dhaka, Dhaka-1000, Bangladesh Institute of Technology Transfer and Innovation, Bangladesh Council of Scientific and Industrial Research, Bangladesh Fexofenadine HCl is a second-generation antihistamine which is commonly used for allergic disorders. But it has low bioavailability. Intranasal corticosteroids (INCs) and Immunotherapy and Allergen Specific Immunotherapy (ASIT) are now commonly being suggested for the treatment of allergic disorders. Despite the fact that current treatment alternatives have been in use for decades, patient quality of life has remained static. The treatment options are not much explored for their respective adverse effects. Therefore, they are in desperate need of research. Fexofenadine HCl is available in the form of a suspension, tablet, or capsule. In our current study, we have explored whether microspheres can be the perfect dosage form of Fexofenadine HCl to treat allergic disorders considering the pharmacokinetics of the drug, available dosage forms options and the probable side effects of the current therapies. https://www.biotech-asia.org/vol18no4/fexofenadine-hcl-microspheres-can-it-be-the-first-line-therapy-for-allergic-disorders/ Allergen Specific Immunotherapy (ASIT);  Allergic disorder; Fexofenadine HCl; Half-life Intranasal corticosteroids (INCs); Microsphere